Physician profile
Peter O Kuponiyi
NPI 1285674010
$8,221.24
in general payments reported to CMS, 2019-2025
58 companies · $712 in 2025
The $712 reported for 2025 was more than what 84% of Addiction Medicine (Internal Medicine) providers received nationally (typical 2025 total: $124).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,289 · 2020: $1,119 · 2021: $1,531 · 2022: $1,186 · 2023: $1,320 · 2024: $1,064 · 2025: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,079 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,079.08 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,015.49 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $990.41 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Sunovion Pharmaceuticals INC. | $620.87 | 2019-2022 | |
| Pfizer INC. | $600.96 | 2019-2025 | |
| Amgen INC. | $492.98 | 2019-2025 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $474.44 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $450.71 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $324.33 | 2019-2024 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $321.28 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lilly USA, LLC | $239.79 | 2019-2024 | Jardiance, Emgality, Zepbound |
| Insulet Corporation | $238.34 | 2023-2025 | Omnipod |
| Kowa Pharmaceuticals America, INC. | $230.03 | 2020-2023 | Livalo, Seglentis |
| Merck Sharp & Dohme LLC | $194.58 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $162.59 | 2019-2023 | Myrbetriq |
| Allergan, INC. | $158.20 | 2019-2020 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Kuponiyi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.